Title |
Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx)
|
---|---|
Published in |
Therapie, January 2017
|
DOI | 10.1016/j.therap.2016.09.017 |
Pubmed ID | |
Authors |
Fabien Lamoureux, Thomas Duflot, the French Network of Pharmacogenetics |
Abstract |
The use of genomic markers to predict drug response and effectiveness has the potential to improve healthcare by increasing drug efficacy and minimizing adverse effects. Polymorphisms associated with inter-individual variability in drug metabolism, transport, or pharmacodynamics of major cardiovascular drugs have been identified. These include single nucleotide polymorphisms (SNP) affecting clinical outcomes in patients receiving antiplatelet agents, oral anticoagulants and statins. Based on clinical evidence supporting genetic testing in the management of cardiovascular diseases using these drug classes, this short review presents clinical guidance regarding current pharmacogenetics implementation in routine medical practice. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 2 | 40% |
Venezuela, Bolivarian Republic of | 1 | 20% |
Canada | 1 | 20% |
Unknown | 1 | 20% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 80% |
Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 34 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 4 | 12% |
Researcher | 3 | 9% |
Student > Bachelor | 3 | 9% |
Student > Master | 3 | 9% |
Student > Ph. D. Student | 2 | 6% |
Other | 6 | 18% |
Unknown | 13 | 38% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 21% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
Biochemistry, Genetics and Molecular Biology | 3 | 9% |
Agricultural and Biological Sciences | 2 | 6% |
Unspecified | 1 | 3% |
Other | 3 | 9% |
Unknown | 15 | 44% |